HealthNEWS

Health Union: Commission signs Joint Procurement contract with HIPRA for COVID-19 vaccines

HERA, the European Fee’s Well being Preparedness and Response Authority, has signed a joint procurement Framework Contract with the corporate HIPRA HUMAN HEALTH for the availability of their protein COVID-19 vaccine. 14 Member States and international locations are collaborating on this joint procurement, beneath which they’ll buy as much as 250 million doses. Because the variety of instances is once more on the rise in Europe, this settlement will make the HIPRA vaccine quickly obtainable to the collaborating international locations, as quickly as this vaccine has acquired a constructive evaluation by the European Medicines Company.

Well being and Meals Security Commissioner Stella Kyriakides stated: “With COVID-19 infections on the rise in Europe, we have to guarantee most preparedness as we head into the autumn and winter months. The HIPRA vaccine provides but another choice to enrich our broad vaccine portfolio for our Member States and residents. A rise in vaccination and boosting is important over the approaching months. We’re working tirelessly to verify there are vaccines obtainable for all. That is our European Well being Union in motion – making ready forward and being able to act.”

The joint procurement contract with HIPRA enhances an already broad portfolio of vaccines secured by the EU Vaccines Technique, together with the contracts already signed with AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica NV, BioNtech-Pfizer, Moderna, Novavax and Valneva. Some 4.2 billion doses have been secured beneath the EU Vaccines Technique. This diversified vaccine portfolio will guarantee Europe continues to be nicely ready for COVID-19 vaccination, utilizing vaccines which were confirmed to be secure and efficient.  Taking part international locations might resolve to donate the vaccines to decrease and middle-income international locations or to re-direct them to different European international locations.

The HIPRA bivalent recombinant protein vaccine, which is presently beneath rolling assessment by the European Medicines Company, is being developed as a booster dose in beforehand immunized individuals 16 years and older. The HIPRA vaccine is saved at refrigerated temperature between 2 and 8ºC, facilitating storage and distribution in Europe and internationally.

Subsequent steps

The COVID-19 vaccine from HIPRA is presently beneath rolling assessment by the European Medicines Company (EMA). If the vaccine receives a advertising authorisation collaborating international locations will be capable of buy the vaccine by the framework contract in place.

Background

Commercial

HERA is a key pillar of the European Well being Union and a basic asset to strengthen the EU’s well being emergency response and preparedness. HERA was established in September 2021 to switch advert hoc options to pandemic administration and response with a everlasting construction with satisfactory instruments and assets to plan the EU motion in case of well being emergencies.

The EU’s Joint Procurement Settlement gives the 36 collaborating international locations to collectively procure medical counter-measures in its place or complement to procurement at nationwide degree. Framework contracts for COVID-19 therapeutics have beforehand been concluded with Hoffmann-La Roche and GlaxoSmithKline Ltd for the acquisition of monoclonal antibodies, in addition to with Gilead for the acquisition of an antiviral. HERA continues to work intently with the collaborating international locations to establish and implement priorities for joint procurement.

Extra data

European Fee’s actions to make sure ample provide of medical countermeasures to help the COVID-19 response

Secure COVID-19 vaccines for Europeans

HERA web site

HIPRA Human Well being

Share this text:

Related Articles

Back to top button
close